Aurora Cannabis launches new medical cannabis products in Canada, Europe and Australia
Updated
Updated · PR Newswire · Apr 28
Aurora Cannabis launches new medical cannabis products in Canada, Europe and Australia
8 articles · Updated · PR Newswire · Apr 28
The expanded portfolio includes dried flower, pre-rolls, and pastilles, with launches in Germany, Poland, Australia, and Canada between now and June 2026.
These products feature diverse strains and formats tailored to local regulatory standards, aiming to meet rising patient and prescriber demand in regulated international medical markets.
Aurora leverages its GMP-certified global manufacturing network to ensure consistent supply and quality, reinforcing its medical-first strategy and leadership in the global medical cannabis industry.
Amid Australia's market crackdown, how will Aurora's shift to premium products impact sales and patient access?
How will the newly acquired Safari Flower facility help Aurora meet diverse European and Australian GMP standards?
Following US rescheduling, what is Aurora's concrete timeline for entering the American medical cannabis market?
As Aurora exits consumer markets, does its medical-only focus risk ceding ground to more diversified competitors?
How does Aurora's investment in genomics translate into superior medical products for patients, not just new strains?
Beyond improving margins, what are the unforeseen strategic risks of divesting the Bevo plant propagation business?